Respiratory disease and early serum S100A12 changes in very premature infants

Abstract

Plasma S100A12 is low in infants with RDS, possibly because of gestationally related differences in neutrophil response or to the effects of antenatal corticosteroids. It is therefore not a useful marker of BPD development.

Biomarkers of Inflammatory Bowel Disease

“…It could be stable for 7 days in room temperature and increases in inflammatory diseases such as arthritis and Kawasaki disease [76, 77]. It also correlated with the prognosis of severe respiratory reaction in premature children [78]. Early diagnosis and inflammation control seem to be quite important for pediatrics; it could avoid long-term or short-term complications.…”

The Role of S100A12 as a Systemic Marker of Inflammation

“…RDS is primarily seen in premature infants and is the consequence of incomplete pulmonary maturation [37]. To date, just one study has examined serum S100A12 in the context of RDS [38]. Loughran-Fowlds et al [38] measured serum S100A12 in a cohort of premature infants and demonstrated lower serum S100A12 on day 1 of life in infants who developed RDS ( P < 0.01).…”

S100A12: A noninvasive marker of inflammation in inflammatory bowel disease

“…Serum S100A12 levels are elevated in individuals with a number of inflammatory conditions such as arthritis and Kawasaki's disease . Elevated levels are associated with adverse respiratory outcomes in premature infants and early onset of airway disease in young children with cystic fibrosis . We have previously demonstrated increased levels in gut mucosa and the serum of children with newly diagnosed IBD .…”